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Abstract
OBJECTIVE: It is well documented that the most common problems associated with diagnostic
and interventional angiography are major bleeding and vascular complications. While previous
research and the American College of Cardiology (ACC) recommend the use of bleeding risk
stratification tools, there is little evidence related to the use of bleeding avoidance strategies in
the high-risk for bleeding population. This study aims to determine if individualizing access site
and anticoagulation strategies based on bleeding risk stratification would positively impact
NCDR Risk-Adjusted Bleeding Rates.
METHODS: This was a single-center pilot study utilizing retrospective chart reviews with
pre/post design. Data was collected on all percutaneous coronary interventions (PCI) from 3
interventionalists excluding ST elevation myocardial infarction (STEMI) and staged chronic total
occlusion (CTO) procedures. Variables analyzed in the study included age, gender, body mass
index (BMI), bleeding risk score, access site, anticoagulation strategy, P2Y12 inhibitor used, use
of GPIIbIIIa inhibitors, use of vascular closure devices, ultrasound use, bleeding events, blood
transfusions and the previous diagnosis of heart failure, end-stage renal disease, and diabetes
mellitus. The study compared baseline data (3 months prior to implementation) to post
implementation data (3 months after implementation).
RESULTS: High bleeding risk patients comprised 14% and 18% of the baseline and post
implementation groups respectively; after exclusion criteria was considered, only 9.4% and
10.7% of the PCI subjects were utilized for analysis. Sample sizes were too small to show
statistically significant differences between the baseline and post implementation groups.
CONCLUSION: Further research is necessary to directly correlate the benefits of individualizing
patient care based on bleeding risk stratification.
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Individualizing Patient Care During Percutaneous Coronary Intervention to Reduce Operator
Risk Adjusted Bleeding Rates: A Pre/Post Interventional Study
Background
Peri-procedural bleeding is a serious risk for the percutaneous coronary intervention
(PCI) patient population. Therefore, as Singh (2015) states, “recognition and mitigation of
bleeding risk following PCI is a recognized health care priority” (p. 2233). Major bleeding and
vascular complications are among the most common complications associated with diagnostic
and interventional angiography (Nelson et al., 2018). Moreover, bleeding complications have
long been cited as direct predictors of prolonged hospital stays, increased short and long-term
morbidity and mortality, and significantly increased financial burden (Singh, 2015). Among
other factors, predictors of major bleeding include patients who are of advanced age, female, or
with renal impairment (Singh, 2015). Bleeding avoidance strategies (BAS) can be utilized to
successfully improve quality of care in patients who are at high risk for major bleeding events.
BAS include use of radial artery access rather than femoral artery when possible; use of
bivalirudin rather and heparin with/without glycoprotein inhibitors; and the use of vascular
closure devices after femoral access for PCI (Khambatta et al., 2016). The American College of
Cardiology (ACC) clinical practice guidelines recommend that all patients be evaluated for
bleeding risk prior to PCI (Levine et al., 2011). Bleeding risk scoring tools can be utilized to
identify patients who are most at risk for major bleeding events and further individualize intra
and post procedural care decisions to maximize patient safety (Kerl et al., 2015).
The National Cardiovascular Data Registries (NCDR) CathPCI registry monitors and can
be used to draw conclusions regarding major bleeding events in cardiac catheterization labs
nationwide. The CathPCI In-Hospital Risk Adjusted Rate of Bleeding (RAB) considers any post
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PCI patient eighteen years or older with a post-PCI bleeding event. The ACC defines post-PCI
bleeding as any of the following: a bleeding event within 72 hours (arterial access site bleeding;
retroperitoneal, gastrointestinal, or genitourinary bleeding); intracranial hemorrhage; cardiac
tamponade; post-procedure hemoglobin decrease of > 4 g/dl and pre-procedure hemoglobin of <
16 g/dl (Rao et al., 2013). As of 2017, a widely known cardiovascular institution in the Midwest
remains above the national benchmark for this measure.
Multiple tools have been shown to be effective in predicting PCI bleeding risk. One
validated tool used widely nationwide is the NCDR CathPCI Bleeding Risk Score. This simple
tool was derived from the national CathPCI database, and can be used in patients who present
with acute coronary syndrome (ACS) or those who are undergoing elective angiography (Singh,
2015). The NCDR Bleeding Risk Score considers the patient’s presentation, status of ST
elevated myocardial infarction (STEMI), age, body mass index (BMI), previous PCI, degree of
renal dysfunction, presentation of shock, recent cardiac arrest, gender, and most recent
hemoglobin result (Rao et al., 2013). Bleeding risk is calculated based on a point system and
categorized (low, intermediate, or high) based on the result. This tool is currently utilized to
evaluate all patients undergoing coronary angiography at the institution of interest for this study.
Once bleeding risk stratification has been established, the operator and care team should utilize
the information to improve patient safety. Data suggest that the employment of BAS in patients
who are at intermediate or high risk for bleeding both improves the safety of the procedure for
vulnerable populations and decreases costs associated with PCI.
Because the risk for bleeding is modifiable (Singh, 2015), it is crucial that intermediate
and high risk patients be identified and treated accordingly. The purpose of this study is to
utilize the Bleeding Risk Score to individualize arterial access and anticoagulation strategies to
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decrease individual operator RAB rates. This is a small pilot study in which the investigator will
follow three high volume physicians and compare their bleeding complication rates before and
after employing the patient appropriate BAS. The question posed for this research is: What is
the effect of using the NCDR CathPCI Bleeding Risk Score for individualized access site and
anticoagulation strategies on individual operator RAB rate?
This project proposes the use of BAS in the patient populations deemed at high risk for
bleeding events peri-procedure. Singh (2015) suggests considering the following for those who
are at increased risk of bleeding: (1) use of radial access; (2) aiming for activated clotting time
(ACT) levels; (3) use of bivalirudin for high risk cases; (4) use of fluoroscopy, ultrasound and
micropuncture techniques to guide femoral access; (5) early sheath removal; and (6) use of
vascular closure devices. The specific aim of this project is to provide evidence to determine if
operator RAB rates are affected by employment of BAS. A secondary goal of this project is to
begin a shift among operators in this environment to utilize the bleeding risk score made
available to them to maximize patient safety. Applying evidence-based practice to the operator’s
normal routine may decrease overall bleeding complications, improve patient outcomes, and
minimize financial costs associated with adverse bleeding events.
Theoretical Framework
The Transtheoretical Model (TTM; Stages of Change) formed the theoretical framework
for this study. Applying the TTM helped us identify the stages of change that the operators faced
while adapting to implement evidence-based practice. The focus was on utilizing tools that are
readily available to optimize patient safety and minimize peri-procedural complications. Nelson
et al. (2018) have discussed the operator preference of femoral access, the lack of use of adjunct
imaging (fluoroscopy and ultrasound) for access, the minimal use of micropuncture needle kits,
9

and the preference of unfractionated heparin as opposed to bivalirudin. The authors further
discussed the disconnect between evidence and practice in this area: experience and comfort with
outdated techniques continue, though evidence clearly shows that a change is warranted (Nelson
et al., 2018).
Review of Literature
Methods
Thorough searches of the PubMed and Scopus databases were completed to obtain
current research on vascular access complications, strategies to avoid bleeding complications,
use of bleeding risk predictor tools, and comparison of the use of heparin versus bivalirudin in
the setting of coronary intervention. The inclusion criteria limited this literature review to
studies and/or reviews published since 2013 to ensure that the most current and relevant
literature was analyzed. Keywords and phrases such as “vascular access complications,”
“bleeding risk score,” “prevention AND complications AND vascular,” “coronary intervention,”
and “bivalirudin AND heparin” were all used for database search purposes. Several
combinations of database search results were utilized to narrow search results further. The
search for evidence yielded a high-quality mixture of randomized controlled studies, systematic
reviews and meta-analyses. The search results were closely examined to include only the highest
level of evidence, related specifically to identifying the high risk PCI population and strategies
which can be employed to decrease vascular complications within this group.
Minimizing Major Bleeding Complications
Despite the equipment and technology advances associated with PCI procedures, periprocedural bleeding remains one of the most common complications in this population (Gargiulo
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et al., 2018; Khambatta et al., 2016; Mehran et al., 2010; Nelson et al., 2018; Numasawa et al.,
2017; Rao, Chhatriwalla et al., 2013; Singh, 2015). More specifically, femoral artery access site
bleeding and hematoma formation are the most common vascular complications associated with
the procedure (Khambatta et al., 2016; Nelson et al., 2018; Pasala et al., 2016; Rashid et al.,
2017). As more potent pharmacological treatment is introduced for prevention of thrombotic
events peri-procedure, a consequence is increased hemorrhagic complications (Mehran et al.,
2010). Bleeding complications following PCI have been correlated to higher patient morbidity
and mortality, as well as prolonged hospitalization and increased costs (Dobies et al., 2015;
Gargiulo et al., 2018; Khambatta et al., 2016; Mehran et al., 2010; Rao, Chhatriwalla et al., 2013;
Rashid et al., 2017; Singh, 2015). Significant predictors of increased bleeding risk associated
with PCI include older age, female gender, femoral artery access, low BMI, and renal
impairment (Dobies et al., 2015; Gargiulo et al., 2018; Khambatta et al., 2016; Rao, McCoy et
al., 2013; Singh, 2015). Utilizing BAS in patient populations who are at highest risk for bleeding
events has been associated with decreased rates of bleeding complications (Khambatta et al.,
2016; Mina, Gobrial, Modi, & Dominic, 2016; Nelson et al., 2018; Rao, Chhatriwalla et al.,
2013; Singh, 2015).
Individualized Bleeding Risk Scoring Tools
Simple tools are available to assist providers in stratifying patients into groups based on
the risk factors for increased bleeding events (Dobies et al., 2015; Kerl et al., 2015; Mehran et
al., 2010; Rao, Chhatriwalla et al., 2013; Rao, McCoy et al., 2013). Various bleed risk
stratification tools exist which utilize point systems for specific patient variables and determine
that patient’s level of risk for peri-procedural bleeding. These models are referred to as bleeding
risk scores (BRS), and it is the NCDR PCI BRS that is most widely used throughout the United
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States (Dobies et al., 2015; Kerl et al., 2015; Rao, Chhatriwalla et al., 2013; Rao, McCoy et al.,
2013). The NCDR PCI BRS was derived from a logistic regression analysis utilized to
determine the pre-PCI variables most predictive of bleeding in a PCI population of more than
300,000 (Kerl et al., 2015). The NCDR PCI BRS model has been updated as recently as 2013 to
identify the most significant risk factors noted in contemporary clinical practice, making it a
useful tool to guide clinical decision-making and support quality improvement (Kerl et al., 2015;
Rao, McCoy et al., 2013).
Radial Versus Femoral Access
Radial artery access certainly decreases bleeding complications among the PCI patient
population and its use is on the rise (Jaswaney et al., 2018; Khambatta et al., 2016; Mina et al.,
2016; Rashid et al., 2017; Singh, 2015). In a large survey conducted in 2016, a great portion
(42%) of cardiologists considered themselves both radialists and femoralists; however, it is
important to note that some providers, as many as 18%, still strongly favor femoral access
(Nelson et al., 2018). While the benefits of radial access are well known, femoral access is the
preferred approach for patients with cardiogenic shock, left main or bifurcation PCI, and
procedures with mechanical circulatory support (Nelson et al., 2018). Other patient populations
in which operators preferred femoral access include end-stage renal disease, known chronic total
occlusion (CTO), concurrent right heart catheterization, history of coronary artery bypass grafts
(CABG), need for rotational atherectomy, and an anticipated need for a sheath larger than 6F
(Nelson et al., 2018).
Useful strategies for decreasing bleeding complications associated with transfemoral
access include: the routine use of a bleeding risk stratification tool, radial access if possible,
lower activated clotting time (ACT) goals, use of bivalirudin for high-risk bleeding scores,
12

judicious and selective use of glycoprotein inhibitors, use of fluoroscopy, ultrasound and
micropuncture needle when gaining femoral access, early sheath removal and the use of vascular
closure devices (Kerl et al., 2015; Mehran et al., 2010; Nelson et al., 2018; Pasala et al., 2016;
Rashid et al., 2017; Singh, 2015). However, Nelson et al. (2018) found in their 2016 survey that,
despite best practice guidelines, 60% of the respondents preferred to use palpation alone when
gaining femoral artery access, only 28% utilized fluoroscopy, and only 12% reported using
ultrasound guidance (Nelson et al., 2018). Furthermore, Nelson et al. (2018) reported that twothirds of their respondents indicated that they never use micropuncture needle kits, a very small
needle which reduces trauma to the artery, when gaining transfemoral access (Murarka and
Movahed, 2014).
Antithrombotic Therapy in Percutaneous Coronary Intervention
Both elective PCI procedures and those in the setting of ACS are associated with a high
risk of thrombotic complications (Chaudry et al., 2018; Gargiulo et al., 2018; Grajek et al., 2018;
Jaswaney et al., 2018; Mina et al., 2016). Evidence of the most effective pharmacotherapy to
successfully reduce thrombotic complications while minimizing the risk of bleeding
complications remains ambiguous. Antithrombotic therapy continues to evolve with newer,
more potent medications available on the market and the measuring and comparing of these
pharmacological strategies are further complicated by the evolution of drug-eluting coronary
stents. Current best practice guidelines include both the use of heparin and bivalirudin for
prevention of stent thrombosis and subsequent infarction; however, the clinical safety regarding
hemorrhagic effects of these therapies is conflicting (Gargiulo et al., 2018; Grajek et al., 2018;
Jaswaney et al., 2018; Kerl et al., 2015; Mina et al., 2016; Nairooz et al., 2014; Pasala et al.,
2016; Saad et al., 2017; Shah et al., 2016). The clinical decision of treatment with heparin versus
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bivalirudin has long been debated. Bivalirudin has been shown to be more efficient at preventing
bleeding complications associated with PCI; however, there is conflicting evidence that there
may be small, but possibly clinically significant, increase in thrombotic events (Gargiulo et al.,
2018; Jaswaney et al., 2018; Kerl et al., 2015; Mina et al., 2016; Pasala et al., 2016).
Conversely, heparin appears to be sufficiently effective in preventing thrombotic events and has
a significant financial advantage, but it has been associated with increased bleeding complication
rates (Chaudry et al., 2018; Gargiulo et al. 2018; Jaswaney et al., 2018). Historically, several
major trials have provided conflicting support for both bivalirudin and heparin, prompting major
swings in clinical use of each. Currently, evidence is mounting that supports the use of
bivalirudin specifically in high risk patient subsets to sufficiently prevent thrombotic events
while mitigating the increased bleeding risk.
Bivalirudin Use in High Risk Patient Subsets
Recent literature supports the use of bivalirudin when patients are identified as high risk
by the NCDR PCI BRS and access will be gained via femoral artery (Kerl et al., 2015; Pasala et
al., 2016; Singh, 2015). However, it is important to understand that there is no benefit to using
bivalirudin in procedures where radial access is utilized, even when the patient is identified as
“high risk” by bleed risk stratification tools (Mina et al., 2016; Pasala et al., 2016).
Agency Description
Setting
The study took place in the Cardiac Cath Lab of a 555-bed acute care hospital located in
the Midwest. The unit has five Cath Lab suites with varying patient volume in each room, each
day. The Cath Lab management team consists of a manager, assistant manager, and three
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coordinators. The lab is staffed by 21 nurses and 15 radiology technologists and there are 10
interventional cardiologists who practice in this environment. This lab completed 3251 left heart
catheterizations in 2019, with 1529 of those proceeding to PCI.
Target Population
The target population for this study is all patients undergoing PCI at this facility. The
study sample included PCI patients from three high volume physicians. Post implementation,
the physicians based their access approach and anticoagulation on the BRS, which is calculated
pre-procedure and included in the Safety Time-Out. Operators were asked to plan radial access
when possible for patients who are considered high risk for bleeding complications (BRS 65 or
greater). If access was gained via femoral artery and the procedure proceeded to angioplasty, the
physician was asked to choose bivalirudin for anticoagulation therapy in the high risk bleeding
score population.
Congruence with Institution’s Mission/Vision
The vision statement of the institution describes being a national leader of personalized
patient experiences, clinical outcomes and affordable care. The institution’s mission statement
includes “providing exceptional outcomes and the finest experiences.” It is important to note the
hospital’s initiative to provide personalized health care, as this is precisely where this study’s
aim is focused; individualizing access site and anticoagulation decisions based on specific patient
characteristics and presentation.
Stakeholders and Their Roles
Stakeholders of this research included patients at high risk for bleeding and their families,
Cath Lab staff, pre-procedural nursing staff, interventional cardiologists, pharmacy staff, Cath
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Lab administration, and hospital administration. Patients presented for an elective, urgent or
emergent cardiac catheterization and expected care to be personalized based on their needs.
Patients who are at increased risk of bleeding can avoid major complications which are often
associated with longer hospital stays, additional diagnostic testing, blood transfusions or
subsequent procedures/surgeries. Patients’ families also had a stakeholder role, as families are
often secondarily affected by longer hospital stays, increased financial responsibilities, increased
care requirements, and subsequent follow-up care appointments or procedures. Pre-procedural
nursing staff played an important role by completing the BRS calculator accurately and in a
timely manner. Clear understanding of the bleeding risk scoring tool was essential. Accuracy
was particularly important, as scoring one factor incorrectly could result in the patient being
stratified in an inappropriate risk category. Nursing staff within the Cath Lab played a
significant role by identifying the high risk for bleeding population and collaborating with the
physician regarding access site intention and anticoagulation strategy if the patient were to need
PCI.
Interventional cardiologists were a key stakeholder in this process, as the decisions to
individualize patient care based on bleeding risk stratification lay with them. Their personal
RAB rate could be greatly impacted by a simple change in practice, making them more proficient
in practice with fewer complications associated with their procedures. Pharmacy staff had an
important role as well, as the use of bivalirudin was low prior to this project, and could have
increased with this research study. It was important for the study to maintain an adequate supply
of bivalirudin readily available in the Cath Lab suites. The Cath Lab administration was an
important stakeholder for this research study as well: it was important for them to maintain the
highest level of safety for the patients in this environment. With bleeding complications being
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one of the most common life-threatening problems associated with this type of procedure, it was
essential to mitigate the risk. Another important stakeholder for this research was the hospital
administration. This is a relatively small private hospital which could be significantly affected
by increased financial responsibility, significantly increased length of stay, and poor patient
outcomes associated with bleeding complications.
Barriers and Facilitators
Barriers are factors that prevent change from being successfully implemented. For the
purpose of this research major barriers included: (1) operator access site preference (2) increased
cost of bivalirudin, (3) anatomical barriers to radial access site, (4) patient allergy listed to
bivalirudin, (5) physician resistance, and (6) provider and nurse education.
Facilitators are factors that enhance successful implementation of change. For this
research, facilitators included: (1) the fact that BRS had previously been implemented at this
facility and was currently being used; (2) the fact that BRS was already included in the preprocedure Safety Time-Out; (3) physician interest in decreasing publicly reported complication
rates; (4) nurse interest in providing optimal patient care and outcomes; (5) administrative
interest in providing safe, effective, and financially responsible care; and (6) the fact that patient
data were already extracted in the CathPCI registry database.
Project Design
This pilot study involved a retrospective chart review with a pre/post design aimed at
decreasing CathPCI Registry calculated RAB rates associated with PCI in a Midwestern acute
care hospital. This research had several specific aims: (1) determine if RAB rates are positively
impacted by specifically identifying high risk bleeding patients and taking appropriate bleeding
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precautions; (2) assess pre and post intervention prevalence of radial access use in the high
bleeding risk population; (3) assess pre and post intervention anticoagulation strategies used; (4)
assess physician reported barriers to optimizing bleeding reduction strategies; (5) assess the
comorbidity burden by analyzing the impact of previously diagnosed diabetes mellitus, heart
failure, end-stage renal disease, and obesity when bleeding events occur in the high risk bleeding
population.
Project Methods
Evidence-Based Intervention
Study physicians were asked to base access site decision and anticoagulation strategy on
the patient’s calculated risk of bleeding. Radial access was preferred in all patients with a high
NCDR CathPCI BRS. Patients with a high BRS who were not candidates for radial access
(anatomically unattainable, procedures requiring large bore catheters, or by choice), received
bivalirudin, unless contraindicated, as opposed to unfractionated heparin for anticoagulation.
Procedures
The NCDR CathPCI BRS (Table 1) is calculated by the pre-procedure area on all patients
who undergo cardiac procedures at this institution. To ensure accuracy, the procedure
circulating nurse re-calculated the BRS for all patients who received care from the study
interventionalist. Access site strategy was to be planned considering the patient’s BRS: radial
access when at all possible for patients considered high risk of bleeding. Patients with a known
left internal mammary bypass graft were considered for access via left radial artery. For patients
who were undergoing right and left heart catheterizations; radial/brachial, radial/internal jugular,
radial subclavian or even radial artery/femoral vein were preferred to femoral artery access. If a
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patient’s upper extremity arterial anatomy was unfavorable, or the provider anticipated using
large bore equipment, femoral artery access was used. If it was deemed necessary to access the
femoral artery in a patient with a high BRS, the interventionalist was asked to utilize bivalirudin
for anticoagulation if PCI was necessary (Figure 1).
The Cath Lab nursing staff was asked to complete a brief survey (Figure 2) on every
patient who had a procedure completed by the study interventionalists. The survey was utilized
to provide qualitative feedback regarding physician reported barriers to the process but was also
designed to prompt nursing staff to consider the appropriate actions for high risk patients.
IRB Approval Process
Institutional Review Board (IRB) approval was obtained from both the University of
Kentucky Medical Center and the study institution. The University of Kentucky’s Office of
Research Integrity approved the project via an expedited review process; informed consent was
waived. Subsequently, the project gained approval at the institution through the process of an
IRB Reliance Agreement.
Implementation
Baseline data collection occurred from September 1st, 2019 through November 30th,
2019. Education of both the study interventionalists and the Cath Lab nurses occurred in
November 2019. Post implementation data were collected from December 1st, 2019 through
February 29th, 2020.
Education began with a thorough discussion with the three study physicians regarding the
purpose and implications of the study and the decision tree for patients deemed at high risk for
bleeding events according to the NCDR CathPCI BRS. One on one teaching was completed
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with each registered nurse in the Cath Lab regarding the need for BRS calculation confirmation
and its implications. Nurses were asked to address access site and potential anticoagulation
strategy with the study physician prior to the start of the procedure. In addition, nurses were
asked to complete a brief information survey for each case completed by the study
interventionalists.
Sample
The sample included all patients who underwent PCI performed by the pilot study
interventional cardiologists from September 1st, 2019 to February 29th, 2020. All PCIs are
recorded in the CathPCI Registry; data from all the study physician cases were extracted for
analysis. The study excluded all patients who were considered STEMI and patients who were
staged for CTO procedures.
Measures and Instruments
Data collection was completed via NCDR CathPCI Registry data extraction and chart
reviews by the investigator. Appropriate subjects (PCIs performed by the study
interventionalists) were identified from the registry database. Variables that were included and
extracted from the database consisted of: medical record number, gender, age, arterial access
site, acute coronary syndrome, bleeding event, blood transfusion, the use of a vascular closure
device, and presence of diabetes mellitus, heart failure, or end-stage renal disease. Variables
which were manually extracted from medical chart review included: NCDR PCI BRS, intraprocedure anticoagulation, P2Y12 inhibitor used, use of GPIIbIIIa inhibitors, and the use of
ultrasound for femoral access. Surveys completed by the Cath Lab nursing staff were reviewed
by the investigator when the study time frame was completed. Data analysis was completed

20

utilizing SPSS data analytic software. Chi square testing was completed to compare variables
between the baseline and post implementation data.
Results
Sample Characteristics
The baseline data consisted of 106 PCIs among the three study operators. Of the baseline
data PCIs, 15 were considered high risk per the risk stratification procedure. There were 29 CTO
procedures and 4 STEMIs, which were excluded. Subsequently, only 10 patients could be used
for data analysis after excluding CTO and STEMI (Table 2).
In the post implementation time frame, there were 56 PCIs among the three
interventionalists, and this group included 10 high bleeding risk patients. The post
implementation data set had 18 CTOs and 5 STEMIs which were excluded from data analysis.
Ultimately, 6 patients were included for data analysis (Table 2).
Of the patients in the baseline data, there were two bleeding “events” as classified by the
NCDR CathPCI Registry, and three patients received blood transfusions; however, these patients
were excluded from the data analysis due to exclusion criteria. Among the patients in the post
implementation data set, there were two with bleeding events, of which one received a blood
transfusion; however, one was excluded due to CTO procedure and the other was not a high risk
patient. Consequently, no bleeding events or blood transfusions were recorded on patients who
were used in data analysis in either group.
Despite the difference in PCI sample size variation, it is significant to note that the
inclusion sample was a similar proportion in each group. Of the 106 baseline data PCIs, 10
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patients were used (9.4%); of the 56 post implementation PCIs, 6 patients were used for data
analysis (10.7%).
Sample Demographics
Demographics that were evaluated for this study included age, gender, and BMI. Ages of
subjects in the baseline group ranged from 66 to 84 years old; ages in the post implementation
group ranged from 60 to 91 years old. In the pre-implementation group 9 out of 10 (90%) were
female, whereas in the post implementation group 2 of 6 (33%) were female. BMIs recorded in
each group were similar. Subjects with BMI between 20-30 comprised 60% and 50% of the pre
and post samples respectively; BMI between 30-40 included 30% and 33%; and BMI of 40+
consisted of one patient in each sample,10% and 16.7% respectively.
Risk-Adjusted Bleeding Rate
Among the patients who were considered at high risk for bleeding and included in the
data analysis, there were no bleeding events recorded. The RAB rate is calculated with the
number of bleeding events as the numerator. Due to the lack of bleeding events in the small
sample analyzed, it is difficult to draw any conclusions regarding the RAB rate.
Comorbidities
Comorbidities that were analyzed in this study included heart failure, diabetes mellitus,
and end-stage renal disease. These were included based on inclusion criteria of the NCDR
CathPCI Registry. Of the subjects in the baseline data, 50% had heart failure, 50% had diabetes
mellitus, and none met the end-stage renal disease criteria. Likewise, in the post implementation
group, 50% had heart failure and 50% had diabetes mellitus; however, 2 patients (30%) did have
end-stage renal disease.
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Bleeding Avoidance Strategies
The BASs that this study examined included the use of radial artery access, the use of
ultrasound when gaining femoral access, and the use of closure devices when femoral access was
utilized. Radial access was used in 30% of cases in the baseline data compared with 16% of
cases in the post implementation group. Ultrasound was utilized when gaining femoral access in
100% of the cases examined in both groups. The use of femoral artery closure devices increased
after implementation; 29% and 40% in the baseline and post implementation groups,
respectively.
Pharmacological Strategies
The study analyzed three pharmacological strategies: intra-procedural anticoagulation,
P2Y12 platelet inhibitor choice, and the use of GPIIbIIIa inhibitors. Heparin was used for
anticoagulation in 100% of subjects in the baseline data; bivalirudin was used in one of five
femoral cases (20%) post implementation. Ticagrelor was the P2Y12 platelet inhibitor of choice
in the baseline group and was used in 80% of the cases; clopidogrel usage increased post
implementation and was used 67% of the time. GPIIbIIIa inhibitors were used less frequently in
the post implementation group (17%) compared to the baseline group (40%).
Physician Reported Barriers
Barriers to applying BAS were assessed utilizing a survey which was completed by the
circulating nurse. Patient history of CABG was cited as the most common barrier to utilizing
radial artery access. Another frequently cited barrier to radial artery access was end stage renal
disease with the presence of or anticipation of dialysis grafts or fistulas in the upper extremities.

23

Other barriers noted on the nurse completed survey included advanced age and previous radial
access difficulties documented.
Discussion
The sample sizes of both the baseline and post implementation groups were too small to
show statistically significant levels of change post implementation. Aside from gender, the
demographics compared among the two groups were very similar, as was the measured
comorbidities. Because female gender increases the bleeding risk score, it was anticipated that
there would be more females than males in the high risk subset. The post implementation group
had fewer females proportionately; however, there was more end-stage renal disease, which
likely contributed to the shift.
There were no bleeding events recorded in either high-risk group, making it difficult to
draw any conclusions associating individualized access site and anticoagulation strategies with
decreased bleeding events. When considering the entire group of PCIs completed by the study
interventionalists, there were two bleeding events recorded in the pre-implementation group: one
which was stratified as high risk but presented as a STEMI and therefore was excluded, and
another which was stratified as intermediate bleeding risk but was also a staged CTO procedure,
which was an exclusion criterion as well.
This study specifically suggested the use of radial access and use of bivalirudin if PCI is
performed via femoral access in the high bleeding risk population. Again, small sample sizes
limit the significance of the findings. Radial access decreased proportionately post
implementation. While this initially appears discouraging, feedback from the nurse survey
indicated that three of the six patients were either hemodialysis patients with grafts or fistulas in
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upper extremities, or peritoneal dialysis patients in which upper extremities are often preserved
for the possibility of future upper extremity dialysis access placement. One of the six subjects in
the post implementation group were accessed radially. One of the five post implementation
subjects who was accessed via femoral artery did receive bivalirudin as opposed to heparin for
anticoagulation, and it was specifically documented in the procedural report that bivalirudin was
chosen due to the high bleeding risk.
There were encouraging secondary findings related to bleeding avoidance and
anticoagulation strategies. The operators who participated in this study have excellent habits of
utilizing ultrasound for femoral artery access. Ultrasound use was documented in 100% of all
femoral PCI cases in both the baseline and post implementation data sets. Although the sample
sizes are too small to be statistically significant, there was an increased use of femoral vascular
closure devices. It is also important to note the decrease in GPIIbIIIa inhibitors and the
increased use of clopidogrel as opposed to ticagrelor.
Implications for Future Nursing Research
The results of this study suggest several implications for the future of research on this
topic. First, it would be important to expand data collection to increase high bleeding risk
sample sizes. If continuing with one institution, there are multiple ways one could increase
inclusion criteria to capture more high risk subjects. Expanding to include diagnostic procedures
would give helpful insight to operator bleeding avoidance habits with the exception of
anticoagulation strategies. Including all interventional cardiologists, CTO procedures, STEMI
cases, and collecting data over longer periods of time are all suggestions to increase inclusion for
a single center study. Another expansion opportunity in future research is the inclusion of
intermediate bleeding risk patients. Singh (2015) discusses the importance of mitigating
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bleeding risk with BAS in both the intermediate and high-risk populations; however, it is
important to note that current research does not suggest the use of bivalirudin in the intermediate
risk population.
To encourage and measure the use of bleeding avoidance strategies, researchers might
also consider focusing on one strategy at a time with all interventional cardiologists in a single
center. Perhaps evidence-based education for all interventionalists and staff on one bleeding
avoidance focus point and monitoring that variable for a period would be more influential.
The institution where this study took place has, since implementation, shifted from
measuring bleeding complications with RAB rates to monitoring bleeding events by capturing
patients who have received blood transfusions post procedure. With this new technique, the
institution does not rely on the NCDR CathPCI Registry bleeding event criteria; instead, they are
investigating all patients who receive post procedure transfusions. Future research could include
examining these post procedure transfusion cases to determine if the bleeding risk stratification
tool is capturing the patients who require blood transfusions as high risk.
Limitations
This study had numerous limitations. The study was a pilot study completed at a single
center, which limited the sample size. The nature of the high bleeding risk subset the study
aimed to investigate narrowed the sample size for data analysis dramatically. The data were
collected over a short period of time, further limiting the sample size. During the post
implementation phase of the data collection, one interventionalist stepped away from the Cath
Lab environment, adding an additional challenge to the sample size. Small sample sizes limit
the ability to find significance and generalize findings in these data.

26

Again, the lack of bleeding events among the high risk patients analyzed limits the ability
to draw any conclusions regarding individualized access site and anticoagulation strategies to
decrease bleeding events.
Conclusion
Bleeding and vascular complications are potentially preventable and have significant
consequences. The ACC recommends using risk stratification tools to identify patients at high
bleeding risk and strategies to decrease access site complications have been thoroughly studied.
Bleeding avoidance strategies that have the potential to impact patient outcomes are readily
available and are inexpensive when compared to potential complications, yet they require
behavior and strategy modifications among interventional cardiologists.
The aim of this study was to determine if individualizing patient care according to their
bleeding risk stratification would be beneficial in preventing bleeding complications associated
with PCI. While this study was able to provide insight into the high bleeding risk population, its
proportion among PCIs, and its characteristics, small sample size limited its ability to reach
significant conclusions related to its objectives. Further research is necessary to directly
correlate the benefits of individualizing patient care based on bleeding risk stratification.
Through the continued study of this patient population we can continue to provide individualized
evidence based practice for high bleeding risk patients.
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Table 1: NCDR CathPCI Bleeding Risk Score
STEMI
Age
BMI
Previous PCI
Chronic
Kidney Disease
Shock
Cardiac arrest
within 24 hour
Female
Hb
PCI Status
Bleeding Risk
(Total)

No
0
< 60
0
< 20
15
No
10
No
0
No
0
No
0
No
0
Hb < 13
5
Elective
0
< 25
Low

Yes
15
60-70
10
20-30
5
Yes
0
Mild
10
Yes
35
Yes
15
Yes
20
13 ≤ Hb < 15
0
Urgent
20
25-65
Intermediate

71-79
15
31-39
0

> 80
20
≥ 40
5

Moderate
25

Dialysis
30

Hb ≥ 15
10
Emergency/Salvage
> 40
> 65
High

Table 2: Sample Characteristics

Pre

Post

Total PCI

106

56

High Risk (all)

15

10

CTO (Excluded)

29

18

STEMI (Excluded)

4

5

High Risk excluding CTO
& STEMI
Bleeding Events

10

6

0

0
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Figure 1: High Risk Access Site and Anticoagulation Strategy

Access Site and
Anticoagulation per
physician choice

No

High BRS
(> 65)

Yes

Yes

Radial Access
Candidate?

Large bore
access required?

Yes
Yes

No

Radial
Access/Heparin

Femoral
Access/Bivalirudin
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Femoral
Access/Bivalirudin

Figure 2: RN Data Collection Form

Patient Label

High Bleeding Risk? (if no, stop here)
Yes

No

Radial Approach?
Yes

No

If not radial, was bivalirudin (Angiomax) utilized for PCI?
Yes

No

N/A

Barriers to radial approach (if not utilized)?
_________________________________
Any known bleeding complications at the conclusion of the case?
Yes

No

Brief Description ________________________________
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